Pre-existing autoimmunity determines type 1 diabetes outcome after Flt3-ligand treatment

Journal of Autoimmunity

Volumn 34, Issue 4, 2010, Pages 445-452

  Van Belle, Tom L ^a   Juntti, Therese ^a   Liao, Jeanette ^a   von Herrath, Matthias G ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Autoimmune diabetes; Autoreactive CD8; Biomarker; Dendritic cells; Flt3 ligand; NOD

Indexed keywords

CD8 ANTIGEN; FLT3 LIGAND; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; TREATMENT RESPONSE;

ANIMALS; AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS; MEMBRANE PROTEINS; MICE; MICE, INBRED NOD; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 77952242738     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.11.010     Document Type: Article

References (48)

1. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358:221-229.
2. Shoda L.K., Young D.L., Ramanujan S., Whiting C.C., Atkinson M.A., Bluestone J.A., et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005, 23:115-126.
3. + T-cell-mediated regulation and type 1 diabetes development in NOD mice. Diabetes 2006, 55:2098-2105.
4. Jansen A., van Hagen M., Drexhage H.A. Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet 1995, 345:491-492.
5. Serreze D.V., Gaskins H.R., Leiter E.H. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J Immunol 1993, 150:2534-2543.
6. Vuckovic S., Withers G., Harris M., Khalil D., Gardiner D., Flesch I., et al. Decreased blood dendritic cell counts in type 1 diabetic children. Clin Immunol 2007, 123:281-288.
7. Chen X., Makala L.H., Jin Y., Hopkins D., Muir A., Garge N., et al. Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood. Clin Immunol 2008, 129:413-418.
8. O'Keeffe M., Brodnicki T.C., Fancke B., Vremec D., Morahan G., Maraskovsky E., et al. Fms-like tyrosine kinase 3 ligand administration overcomes a genetically determined dendritic cell deficiency in NOD mice and protects against diabetes development. Int Immunol 2005, 17:307-314.
9. Vasquez A.C., Feili-Hariri M., Tan R.J., Morel P.A. Qualitative and quantitative abnormalities in splenic dendritic cell populations in NOD mice. Clin Exp Immunol 2004, 135:209-218.
10. Prasad S.J., Goodnow C.C. Cell-intrinsic effects of non-MHC NOD genes on dendritic cell generation in vivo. Int Immunol 2002, 14:677-684.
11. Steptoe R.J., Ritchie J.M., Harrison L.C. Increased generation of dendritic cells from myeloid progenitors in autoimmune-prone nonobese diabetic mice. J Immunol 2002, 168:5032-5041.
12. Boudaly S., Morin J., Berthier R., Marche P., Boitard C. Altered dendritic cells (DC) might be responsible for regulatory T cell imbalance and autoimmunity in nonobese diabetic (NOD) mice. Eur Cytokine Netw 2002, 13:29-37.
13. Clare-Salzler M.J., Brooks J., Chai A., Van Herle K., Anderson C. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest 1992, 90:741-748.
14. Chilton P.M., Rezzoug F., Fugier-Vivier I., Weeter L.A., Xu H., Huang Y., et al. Flt3-ligand treatment prevents diabetes in NOD mice. Diabetes 2004, 53:1995-2002.
15. Lyman S.D., James L., Vanden Bos T., de Vries P., Brasel K., Gliniak B., et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993, 75:1157-1167.
16. Brasel K., McKenna H.J., Morrissey P.J., Charrier K., Morris A.E., Lee C.C., et al. Hematologic effects of flt3 ligand in vivo in mice. Blood 1996, 88:2004-2012.
17. Tan J.K., O'Neill H.C. Concise review: dendritic cell development in the context of the spleen microenvironment. Stem Cells 2007, 25:2139-2145.
18. + dendritic cells in vivo. J Exp Med 2003, 198:305-313.
19. D'Amico A., Wu L. The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J Exp Med 2003, 198:293-303.
20. + regulatory T cell function. Clin Immunol 2009, 131:260-270.
21. Amrani A., Verdaguer J., Serra P., Tafuro S., Tan R., Santamaria P. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 2000, 406:739-742.
22. Trudeau J.D., Kelly-Smith C., Verchere C.B., Elliott J.F., Dutz J.P., Finegood D.T., et al. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest 2003, 111:217-223.
23. Maraskovsky E., Brasel K., Teepe M., Roux E.R., Lyman S.D., Shortman K., et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996, 184:1953-1962.
24. Mora C., Wong F.S., Chang C.H., Flavell R.A. Pancreatic infiltration but not diabetes occurs in the relative absence of MHC class II-restricted CD4 T cells: studies using NOD/CIITA-deficient mice. J Immunol 1999, 162:4576-4588.
25. Wicker L.S., Leiter E.H., Todd J.A., Renjilian R.J., Peterson E., Fischer P.A., et al. Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes 1994, 43:500-504.
26. Han B., Serra P., Yamanouchi J., Amrani A., Elliott J.F., Dickie P., et al. Developmental control of CD8 T cell-avidity maturation in autoimmune diabetes. J Clin Invest 2005, 115:1879-1887.
27. + T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase. J Immunol 2004, 173:6727-6734.
28. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
29. Ansari M.J., Salama A.D., Chitnis T., Smith R.N., Yagita H., Akiba H., et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003, 198:63-69.
30. + CD25(Hi) regulatory T cells. Int Immunol 2009, 21:1065-1077.
31. + regulatory T-cell activity to suppress alloimmune responses. Transplantation 2007, 83:774-782.
32. Ohsugi T., Kurosawa T. Increased incidence of diabetes mellitus in specific pathogen-eliminated offspring produced by embryo transfer in NOD mice with low incidence of the disease. Lab Anim Sci 1994, 44:386-388.
33. Wong F.S., Karttunen J., Dumont C., Wen L., Visintin I., Pilip I.M., et al. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med 1999, 5:1026-1031.
34. + T cell clonotype AI4. J Immunol 2004, 173:2530-2541.
35. + T-cell responses change after type 1 diabetes diagnosis and treatment. Diabetes 2008, 57:1312-1320.
36. + T cells in NOD mice. Immunol Rev 2005, 204:250-263.
37. Wang C.J., Chou F.C., Chu C.H., Wu J.C., Lin S.H., Chang D.M., et al. Protective role of programmed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models. Diabetes 2008, 57:1861-1869.
38. Darrasse-Jeze G., Deroubaix S., Mouquet H., Victora G.D., Eisenreich T., Yao K.H., et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med 2009, 206:1853-1862.
39. + regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 2008, 57:113-123.
40. + T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes 2006, 55:158-170.
41. Machen J., Harnaha J., Lakomy R., Styche A., Trucco M., Giannoukakis N. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol 2004, 173:4331-4341.
42. Karjalainen J.K. Islet cell antibodies as predictive markers for IDDM in children with high background incidence of disease. Diabetes 1990, 39:1144-1150.
43. Srikanta S., Ganda O.P., Gleason R.E., Jackson R.A., Soeldner J.S., Eisenbarth G.S. Pre-type I diabetes. Linear loss of beta cell response to intravenous glucose. Diabetes 1984, 33:717-720.
44. Keskinen P., Korhonen S., Kupila A., Veijola R., Erkkila S., Savolainen H., et al. First-phase insulin response in young healthy children at genetic and immunological risk for type I diabetes. Diabetologia 2002, 45:1639-1648.
45. Panina-Bordignon P., Lang R., van Endert P.M., Benazzi E., Felix A.M., Pastore R.M., et al. Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med 1995, 181:1923-1927.
46. Panagiotopoulos C., Qin H., Tan R., Verchere C.B. Identification of a beta-cell-specific HLA class I restricted epitope in type 1 diabetes. Diabetes 2003, 52:2647-2651.
47. Skowera A., Ellis R.J., Varela-Calvino R., Arif S., Huang G.C., Van-Krinks C., et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008, 118:3390-3402.
48. Wenzlau J.M., Juhl K., Yu L., Moua O., Sarkar S.A., Gottlieb P., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007, 104:17040-17045.